BioSpace News Archive

ResMed announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, beginning at approximately 8:45 a.m. at the Sheraton New York in New York City.

Gb Sciences, Inc. describes their progress towards achieving significant milestones in their drug development pipeline in an article published in the journal Pharma’s Almanac.

Demonstrating another key achievement, Microbot Medical Inc. (Nasdaq: MBOT), continues to execute its objective of expanding its global intellectual property (IP) portfolio for the LIBERTY® Robotic System as a grant for two Design Patent Applications was issued by the European Patent Office (EPO), covering the LIBERTY Robotic System’s Robotic Drive and Remote Controller.

PrepMD RMS, the premier cardiac clinical solutions company, announced today the acquisition of the intellectual property and technology assets of LindaCare, a digital health company specializing in remote monitoring

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, today announced the closing of its initial public offering (IPO) of 1,225,888 units of common stock and warrants at a public offering price of $8.125 per unit.

Hovione, the leader in spray drying and particle engineering, announced that it has expanded its continuous manufacturing offering and services.

Alira Health, a patient-centric, global health care advisory, clinical research and technology company, announced the acquisition of Artisan Healthcare Consulting, a US-based consulting firm that provides strategic insights to healthcare companies.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC (“Cellvera”), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.

Patients Choice Laboratories announced that it has been awarded accreditation from the College of American Pathologists based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.

Elixiron Immunotherapeutics, a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its interferon-gamma-neutralizing human antibody, EI‑001 for the treatment of hemophagocytic lymphohistiocytosis (HLH).